#### Acknowledgement of Country

- The University of Queensland (UQ) acknowledges the Traditional Owners and their custodianship of the lands on which we meet.
- We pay our respects to their Ancestors and their descendants, who continue cultural and spiritual connections to Country.
- We recognise their valuable contributions to Australian and global society.



#### THE UNIVERSITY OF QUEENSLAND AUSTRALIA

## **General Information:**

• We are currently located in Building 69



Emergency evacuation point

- Food court and bathrooms are in Building 63
- If you are experiencing cold/flu symptoms or have had COVID in the last 7 days please ensure you are wearing a mask for the duration of the module



#### Data Agreement



To maximize your learning experience, we will be working with genuine human genetic data, during this module.

Access to this data requires agreement to the following in to comply with human genetic data ethics regulations

Please email <u>pctgadmin@imb.uq.edu.au</u> with your name and the below statement to confirm that you agree with the following:

"I agree that access to data is provided for educational purposes only and that I will not make any copy of the data outside the provided computing accounts."

## Plan for the Module: Genetic Mapping



| 11:30am                    | Q&A session with Dr Loic Yengo |
|----------------------------|--------------------------------|
| 9.4Jaiii                   | 11. Fine mapping               |
| 0.15 m                     | 10. Gene based tests &         |
| oann                       | 9. Finding independent loci    |
| Rom                        | 8. Meta-analysis &             |
| DAY 2 – Post-GWAS analysis |                                |





JΖ



THE UNIVERSITY OF OUEENSLAN

Alesha

Tian



Ang





# Acknowledgements

I wish to acknowledge the following people for allowing me to use/adapt their material (slides and practical) in this module:

Allan McRae Ben Hayes Joanna Revez Jian Zeng Alesha Hatton Ang Li Naomi Wray

Various internet resources & GWAS protocol papers

Prac testers: Giulio, Tian, JZ, Em, Li



# Introduction to Genome Wide Association Studies (GWAS)



## What is a GWAS?

• A Genome Wide Association Study is a hypothesis-free method for identifying associations between locations in the genome and a trait of interest

- Three key parts to a GWAS:
  - $\circ$  A trait of interest or phenotype
  - Genetic markers measured across the genome
  - Statistical test of association between markers & phenotype



#### **Example:** Binary trait





# Example: Quantitative trait



• Linear model:







#### e.g.

#### GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

Elena López-Isac ☑, Marialbert Acosta-Herrera, Martin Kerick, Shervin Assassi, Ansuman T. Satpathy, <u>Nature Communications</u> 10, Article number: 4955 (2019) | <u>Cite this article</u> 12k Accesses | 67 Citations | 35 Altmetric | <u>Metrics</u>

#### Abstract

Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide hits reported for SSc thus far. We define 95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify specific SSc subtype-associated signals. Functional analysis of high-priority variants shows the potential function of SSc signals, with the identification of 43 robust target genes through HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for the disease. This work supports a better understanding of the genetic basis of SSc and provides directions for future functional experiments.



#### e.g.

#### GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

Elena López-Isac ⊡, Marialbert Acosta-Herrera, Martin Kerick, Shervin Assassi, Ansuman T. Satpathy, <u>Nature Communications</u> 10, Article number: 4955 (2019) | <u>Cite this article</u> 12k Accesses | 67 Citations | 35 Altmetric | <u>Metrics</u>

#### Abstract

Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide hits reported for SSc thus far. We define 95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify specific SSc subtype-associated signals. Functional analysis of high-priority variants shows the potential function of SSc signals, with the identification of 43 robust target genes through HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for the disease. This work supports a better understanding of the genetic basis of SSc and provides directions for future functional experiments.

study design

key result

fine mapping & biological interpretation



#### GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

Elena López-Isac 🖂, Marialbert Acosta-Herrera, Martin Kerick, Shervin Assassi, Ansuman T. Satpathy,





## What is a GWAS?

• Conceptually, a GWAS is straight forward. However, LOTS can go wrong!

• Most of the time in GWAS is spent in preparing the data to avoid various pitfalls



# Brief history of GWAS

#### 2005: one of the first GWAS, age-related macular degeneration

• Klein et al. 2005 Science; 96 cases and 50 controls; 116,204 SNPs



#### WTCCC Wellcome Trust Case-Control Consortium

- First large scale GWAS (2007)
- 14,000 cases over 7 diseases
- 3,000 shared controls
- 500K Affymetrix GeneChip



Chromosome



## GWAS – 'hypothesis free' but dependent on frequency

Box 7 | Low-frequency variants and disease susceptibility





# GWAS – 'hypothesis free' but dependent on frequency



**Figure 2. Mutations with intermediate effect (0.**1 to 1 SD units) and low frequency (0.01 to 0.001) are not detected efficiently by either linkage or genome-wide association studies. Shown are the allele effect size (x-axis) and frequency (y-axis) for GWAS results from Lango Allen *et al.* [7] and for the sample of mutations described in Table 1. Assumptions for frequencies and effect of mutations from Table 1 are noted in the table footer.

Kemper et al. (2005) Genome Biology

# Trends in GWAS





The growth of GWAS, 2007–2017. The upper panel shows the number of study accessions published per quarter over time colored according to sample size to show the growth of larger (100,001 $\leq$ N) GWAS. The lower left panel shows the strong positive correlation between the number of associations found and the number of participants used in GWAS over time. The lower right panel shows the growth in the number of unique traits examined as well as the number of unique journals publishing GWAS over time. 2007–2017 is selected since only 10 entries occurred before 2007. Each panel contains full calendar years only. Source: NHGRI-EBI GWAS Catalog

- More genetic markers
- Bigger sample sizes + meta-analysis
- New traits & diseases
- More discoveries + insights

• Predominately EUR ancestry recruited from US, UK & Iceland



## Latest (published) GWAS has 5.4M people!

 Q&A with Loic Yengo (1<sup>st</sup> author) tomorrow

#### Article

# A saturated map of common genetic variants associated with human height

https://doi.org/10.1038/s41586-022-05275-y Received: 19 December 2021 Accepted: 24 August 2022 Published online: 12 October 2022 Open access Check for updates Common single-nucleotide polymorphisms (SNPs) are predicted to collectively explain 40–50% of phenotypic variation in human height, but identifying the specific variants and associated regions requires huge sample sizes<sup>1</sup>. Here, using data from a genome-wide association study of 5.4 million individuals of diverse ancestries, we show that 12,111 independent SNPs that are significantly associated with height account for nearly all of the common SNP-based heritability. These SNPs are clustered within 7,209 non-overlapping genomic segments with a mean size of around 90 kb, covering about 21% of the genome. The density of independent associations varies across the genome and the regions of increased density are enriched for biologically relevant genes. In out-of-sample estimation and prediction, the 12,111 SNPs (or all SNPs in the HapMap 3 panel<sup>2</sup>) account for 40% (45%) of phenotypic variance in



## In conclusion

#### 3 key considerations in GWAS design

phenotypes, genotypes, statistical tests

#### GWASs have led to important discoveries since early 2000's

Primary goal -> biological insight into disease (requires follow-up) Can learn about genetic architecture of trait Limitations

Conceptually a simple idea but care is required

## Plan for the Module: Genetic Mapping



| 11:30am                    | Q&A session with Dr Loic Yengo |
|----------------------------|--------------------------------|
| 9.4Jaiii                   | 11. Fine mapping               |
| 0.15 m                     | 10. Gene based tests &         |
| oann                       | 9. Finding independent loci    |
| Som                        | 8. Meta-analysis &             |
| DAY 2 – Post-GWAS analysis |                                |





JΖ



THE UNIVERSITY OF OUEENSLAN

Alesha

Tian



Ang





## Objective for the Module: Genetic Mapping

- during the module you will *not* find recipes and/or pipelines
- I hope you will *understand* what your doing & be able to critique others





#### Objective for the Module: Genetic Mapping

Take home messages for today...

- Beware of biases
- Multiple testing